Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Bone metastasis (BM) frequently occurs in various types of cancer, particularly in prostate (PCa), breast (BCa), renal (RCC), and lung cancers (LCa), yet no reliable biomarker has been established. In this study, we evaluated the clinical utility of serum growth differentiation factor 15 propeptide (sGDPP), secreted by both osteoblasts and osteoclasts, as a diagnostic biomarker for BM across common solid tumors. A total of 799 participants were enrolled, including 107 healthy donors, 242 patients with PCa, 113 patients with BCa, 159 patients with RCC, and 178 patients with LCa. Among the cancer patients, 398 had no BM and 294 had BM. The diagnostic performance for BM was compared among conventional biomarkers: alkaline phosphatase (ALP), lactate dehydrogenase (LDH), estimated glomerular filtration rate, osteocalcin, bone-specific alkaline phosphatase, tartrate-resistant acid phosphatase 5b, procollagen type I N-terminal propeptide (PⅠNP), and sGDPP. Among all patients, ALP, LDH, PⅠNP, and sGDPP levels were significantly higher in patients with BM than in those without BM. Particularly, sGDPP showed the highest area under the curve values (0.91 in PCa, 0.80 in BCa, 0.81 in RCC, and 0.51 in LCa). Multivariate analysis showed sGDPP is an independent diagnostic biomarker for BM in PCa, BCa, and RCC (p < 0.01). Additionally, sGDPP in patients with osteoporosis did not significantly differ from that in healthy donors, suggesting that sGDPP increases only when tumor cells seed and proliferate in the bones. Overall, sGDPP demonstrated superior diagnostic performance compared to conventional biomarkers and may complement imaging tests in detecting BM.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical implications of serum GDF15 propeptide as a biomarker for bone metastasis across common solid tumors: a real-world multi-institutional study
- Date Crossref
- 12/08/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Osaka Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Osaka International Cancer Institute Department of Breast and Endocrine Surgery pays non établi dans la noticeÉtablissement de santé
-
Kanagawa Prefectural Hospital Organization pays non établi dans la noticeÉtablissement de santé
-
Tosoh (Japan) pays non établi dans la noticeEntreprise
-
Osaka University Hospital pays non établi dans la noticeÉtablissement de santé
-
Osaka Rosai Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Fukushima Medical University Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Kanagawa Cancer Center Research Institute Molecular Pathology and Genetics Division pays non établi dans la noticeStructure de recherche
-
Bioscience Division pays non établi dans la noticeInstitution
-
Iwase General Hospital Department of Urology pays non établi dans la noticeÉtablissement de santé
Department of Urology — The University of Osaka, Department of Breast and Endocrine Surgery — Osaka International Cancer Institute et Kanagawa Prefectural Hospital Organization, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.